Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score

[1] Polascik TJ(1999)Prostate specific antigen: a decade of discovery--what we have learned and where we are going J Urol 162 293-306

[2] Oesterling JE(2010)Analysis of NSAID-activated gene 1 expression in prostate cancer Urol Int 84 198-202

[3] Partin AW(2013)Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission Inflamm Bowel Dis 19 779-784

[4] Kawahara T(2013)Hip fractures and pain following proton therapy for management of prostate cancer Acta Oncol 52 486-491

[5] Ishiguro H(2009)Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values BJU Int 104 800-805

[6] Hoshino K(2000)Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer BJU Int 86 449-452

[7] Teranishi J(2011)Fracture risk in men with prostate cancer: a population-based study J Bone Mineral Res Off J Am Soc Bone Mineral Res 26 1808-1815

[8] Miyoshi Y(2005)Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 154-164

[9] Kubota Y(2012)Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy BJU Int 109 13-21

[10] Uemura H(1999)Density predicts the activity-dependent failure load of proximal femora with defects Skelet Radiol 28 90-95

[1] Polascik TJ(1999)Prostate specific antigen: a decade of discovery--what we have learned and where we are going J Urol 162 293-306

[2] Oesterling JE(2010)Analysis of NSAID-activated gene 1 expression in prostate cancer Urol Int 84 198-202

[3] Partin AW(2013)Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission Inflamm Bowel Dis 19 779-784

[4] Kawahara T(2013)Hip fractures and pain following proton therapy for management of prostate cancer Acta Oncol 52 486-491

[5] Ishiguro H(2009)Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values BJU Int 104 800-805

[6] Hoshino K(2000)Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer BJU Int 86 449-452

[7] Teranishi J(2011)Fracture risk in men with prostate cancer: a population-based study J Bone Mineral Res Off J Am Soc Bone Mineral Res 26 1808-1815

[8] Miyoshi Y(2005)Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 154-164

[9] Kubota Y(2012)Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy BJU Int 109 13-21

[10] Uemura H(1999)Density predicts the activity-dependent failure load of proximal femora with defects Skelet Radiol 28 90-95